Biopolitical Times

The Center for Genetics and Society blog highlights the latest developments in the social, political, and ethical implications of human biotechnologies, with contributions from staff, fellows, consultants, and guest authors.

Black silhouette of pregnant woman against vibrant orange and red sunset

First 3-person IVF pregnancies planned in UK

By Leah Lowthorp | 02.07.2018

As we learned last Friday, the UK’s Human Fertilisation and Embryology Authority (HFEA) has given Newcastle Fertility Centre the green light to create embryos using 3-person IVF techniques and implant them in two women affected by mitochondrial disease. The aim is to create children that are unaffected by mitochondrial disease, yet fully genetically related to both parents. While pre-implantation genetic diagnosis (PGD) is successful in preventing the transmission of mitochondrial disease in most cases, these two cases were deemed exceptions....

Other Countries

Personal Genomics Meets Blockchain

By Pete Shanks | 02.27.2018

Biopolitical Times

The launch of a genomics company with a difference was announced earlier this month. The individual customers who sign up to have their genomes marketed by Nebula Genomics will own their own data, keep it private and rent it to researchers and drug companies, fully anonymized. At least that’s the idea. The company aims to combine state-of-the-art genome sequencing with blockchain technology, the power behind the hugely hyped “digital currency” Bitcoin.

This approach has some practical problems, discussed below,...

Biotech & Pharma

What Just Happened? Looking Back at 2017’s Human Germline Editing Developments

By Leah Lowthorp and Katie Hasson | 01.10.2018

Last January, CGS predicted that gene editing would be one of the biggest science stories of the year. This has been proven true in the numerous developments that unfolded in 2017, in areas ranging from gene drive to gene-edited animals...

Human Genetic Modification

CRISPR Opportunities … For What? And For Whom?

By Pete Shanks, Biopolitical Times | 12.04.2014

Money and deals are flowing into the companies founded on CRISPR technology, which promises to enable the precise editing of genomes.

CRISPR/Cas9 stands for “clustered, regularly interspaced, short palindromic repeat” and an associated protein (not always mentioned). A...

U.S. Federal

Biopolitical Times

First 3-person IVF pregnancies planned in UK

Personal Genomics Meets Blockchain

What Just Happened? Looking Back at 2017’s Human Germline Editing Developments

CRISPR Opportunities … For What? And For Whom?

AncestryDNA Markets Genetic “Greatness” during the Olympics

What if we told you we could back up your mind?

Dog Cloning Headlines — Again

Who Knew Genomics Could Be So Complicated?

Pop Culture and Policy: Can Works of Art Shed Insight on Synthetic Embryos?

What Just Happened? Looking Back at 2017’s Human Germline Editing Developments

Remembering Abby Lippman

So You Got a DNA Test for Christmas. What Now?